🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

BrightGene Bio-Medical Technology clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China and USA registers with BrightGene Bio-Medical Technology as lead sponsor. Synced 26 Sep 2026
11Current trials
10Recruiting now
5Drugs in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

BrightGene Bio-Medical Technology is the lead sponsor of 11 current clinical trials in our China and USA registers. 10 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are BGM0504, BGM1812 and BGM0504 Administered. The most-studied condition is Non-diabetic Overweight or Obese.

ClinicalTrials.gov trials by status

  • Recruiting1091%
  • Not yet open19%

Trials by phase

  • Phase 1655%
  • Phase 3327%
  • Phase 2218%
01

Clinical trials sponsored by BrightGene Bio-Medical Technology

11 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Bioequivalence Study of BGM0504 Injection
NCT07382908 · ClinicalTrials.gov ↗ · Overweight/Obesity
Phase 1 Recruiting 2025-12 China
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects
NCT07166081 · ClinicalTrials.gov ↗ · Non-diabetic Overweight or Obese
Drug: BGM0504
Phase 1 Recruiting 2025-08 USA
A Study of BGM0504 Tablets in Healthy Chinese Subjects
NCT07566572 · ClinicalTrials.gov ↗ · Chinese Healthy Volunteers
Drug: BGM0504
Phase 1 Recruiting 2026-03 China
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women
NCT07224399 · ClinicalTrials.gov ↗ · Healhty, Overweight or Obesity
Drug: BGM1812
Phase 1 Recruiting 2025-10 USA
A Study of BGM0504 in Participants With Obesity
NCT06911203 · ClinicalTrials.gov ↗ · Obesity
Phase 2 Recruiting 2025-04 China
A Study of BGM0504 in Participants with Type 2 Diabetes
NCT06716216 · ClinicalTrials.gov ↗ · Type 2 Diabetes Mellitus (T2DM)
Phase 3 Recruiting 2024-11 China
A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants
NCT07294235 · ClinicalTrials.gov ↗ · Overweight or Obesity
Drug: BGM1812
Phase 1 Recruiting 2025-12 China
A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese Subjects
NCT07239973 · ClinicalTrials.gov ↗ · Healthy, Non-diabetic Overweight or Obese
Phase 1 Recruiting 2025-10 China
A Study of BGM0504 in Early T2DM With Obesity
NCT07743983 · ClinicalTrials.gov ↗ · Type 2 Diabetes (T2DM)
Phase 3 Recruiting 2026-08 China
A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
NCT06716203 · ClinicalTrials.gov ↗ · Type 2 Diabetes Mellitus (T2DM)
Phase 3 Recruiting 2024-12 China
A Study to Evaluate Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without Diabetes
NCT07658560 · ClinicalTrials.gov ↗ · Overweight or Obese Participants Without Diabetes
Phase 2 Not yet open 2026-06 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in BrightGene Bio-Medical Technology trials

5 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in BrightGene Bio-Medical Technology trials

10 conditions
Non-diabetic Overweight or Obese2Overweight or Obesity2Type 2 Diabetes Mellitus (T2DM)2Healhty1Overweight/Obesity1Chinese Healthy Volunteers1Obesity1Healthy1Type 2 Diabetes (T2DM)1Overweight or Obese Participants Without Diabetes1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China98
Clinical trials in USA22

A trial with sites in more than one country appears in each of those registers.

05

Questions about BrightGene Bio-Medical Technology trials

How many clinical trials does BrightGene Bio-Medical Technology sponsor?

BrightGene Bio-Medical Technology is the lead sponsor of 11 current trials on ClinicalTrials.gov in our China and USA registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are BrightGene Bio-Medical Technology trials recruiting?

Yes. 10 of its 11 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is BrightGene Bio-Medical Technology testing?

Its current trials name 5 drugs and biologicals as interventions. The most frequent are BGM0504 (4), BGM1812 (2), BGM0504 Administered (1), Semaglutide (1) and Tirzepatide (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.